Rational peptide-based tumour vaccine development and T cell monitoring
- 31 December 2003
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 13 (6) , 423-429
- https://doi.org/10.1016/j.semcancer.2003.09.006
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicityLeukemia, 2003
- Adjuvant Immunization of HLA-A2–Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+T-Cell ResponsesJournal of Clinical Oncology, 2003
- Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based VaccinesJournal of Clinical Oncology, 2002
- Long‐term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptidesInternational Journal of Cancer, 2002
- In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cellsEuropean Journal of Immunology, 2002
- Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological TherapyJournal of Immunotherapy, 2002
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999
- A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk MelanomaJournal of Immunotherapy, 1999
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991